A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 133 participants.
Also called NCT03338426
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 133 participants
- Registry
-
NCT03338426
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT03338426. Randomized; triple masking; primary purpose treatment. Start 2018-01-15 (actual); primary completion 2019-04-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia
- Acronym
- FIESTA
- Condition
- Essential Hypertension, Dyslipidemia
- Intervention (Drug)
- Fimasartan 120mg
- Intervention (Drug)
- Atorvastatin 40mg
- Intervention (Drug)
- Placebo for Fimasartan 120mg
- Intervention (Drug)
- Placebo for Atorvastatin 40mg
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct03338426- Content hash
17055054eb2c41cbcf06899d88b27f333a1c7ccee39a513e268e7048391a7324